期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
应用基因芯片直接检测结核病患者各类标本中利福平和异烟肼耐药的价值 被引量:18
1
作者 白雪娟 刘银萍 +2 位作者 张俊仙 王杰 吴雪琼 《中国防痨杂志》 CAS CSCD 2019年第2期138-144,共7页
目的研究结核分枝杆菌(MTB)耐药基因芯片直接检测结核病患者临床标本中利福平和异烟肼耐药相关基因的临床价值。方法回顾性分析125例通过硝基苯甲酸(PNB)和噻吩-2-羧酸肼(TCH)鉴别培养为MTB的临床标本,其中痰标本90例、支气管灌洗液12... 目的研究结核分枝杆菌(MTB)耐药基因芯片直接检测结核病患者临床标本中利福平和异烟肼耐药相关基因的临床价值。方法回顾性分析125例通过硝基苯甲酸(PNB)和噻吩-2-羧酸肼(TCH)鉴别培养为MTB的临床标本,其中痰标本90例、支气管灌洗液12例、脓液12例、胸腔积液6例、组织标本3例、腹腔积液和尿液标本各1例,应用绝对浓度法同时进行利福平(RFP)和异烟肼(INH)药物敏感性试验(简称“绝对浓度法药敏试验”),并用基因芯片直接检测临床标本中MTBrpoB、katG和inhA基因型。以绝对浓度法药敏试验为标准,评价基因芯片检测RFP、INH耐药和耐多药(MDR)的敏感度和特异度,并且比较两种检测结果的一致性。结果在125例结核病患者临床标本中,绝对浓度法药敏试验显示对RFP、INH的耐药率和MDR发生率分别为20.0%(25/125)[其中高耐占88.0%(22/25)、低耐占12.0%(3/25)]、17.6%(22/125)[其中高耐占18.2%(4/22)、低耐占81.8%(18/22)]、16.8%(21/125)。初治和复治结核病患者临床标本中MDR-MTB的检出率分别为7.6%(7/92)和39.4%(13/33)。以绝对浓度法药敏试验为标准,应用基因芯片直接检测临床标本中MTBrpoB、katG和inhA基因型,预示对RFP、INH耐药和MDR的敏感度分别为72.0%(18/25)、63.6%(14/22)和61.9%(13/21),特异度分别为91.0%(91/100)、86.4%(89/103)和89.4%(93/104),两种方法的一致率分别为87.2%(109/125)、82.4%(103/125)和84.8%(106/125)。结论应用耐药基因芯片直接检测结核病患者临床标本中MTB对RFP和INH耐药的相关基因突变具有中等的敏感度和较高的特异度,可快速检出对RFP、INH耐药和MDR-TB患者,为临床早期开展有效化疗提供实验依据。 展开更多
关键词 标本制备 结核 抗多种药物性 核酸探针 点突变 微生物敏感性试验 利福平 异烟肼 对比研究
下载PDF
Diagnostic performance and problem analysis of commercial tuberculosis antibody detection kits in China 被引量:10
2
作者 xue-juan bai You-Rong Yang +5 位作者 Jian-Qin Liang Hui-Ru An Jie Wang Yan-Bo Ling Zhong-Yuan Wang Xue-Qiong Wu 《Military Medical Research》 SCIE CAS 2018年第3期242-250,共9页
Background: The diagnosis of bacterium-negative pulmonary tuberculosis(TB) and extra-pulmonary TB is challenging clinically. The detection of the anti-TB antibody has an important, auxiliary, clinical diagnostic value... Background: The diagnosis of bacterium-negative pulmonary tuberculosis(TB) and extra-pulmonary TB is challenging clinically. The detection of the anti-TB antibody has an important, auxiliary, clinical diagnostic value. Therefore, TB antibody detection kits should be screened and evaluated, and the reagents with the highest sensitivity and specificity should be chosen and used clinically.Methods: The diagnostic performance of 7 commercially available TB antibody detection kits(kits A, B, C, D, E, F and G) based on the gold immunoassay detection of immunoglobulin(Ig) G or IgM antibodies were simultaneously evaluated and compared in 62 TB cases and 56 non-TB cases in a laboratory. A retrospective analysis including 2549 cases was carried out to assess the clinical diagnosis values of bacteriological examinations and TB antibody tests(kits B and H used in the clinic).Results: The sensitivities of TB antibody kits A, B, C, D, E, F and G in the sera from 62 TB patients were 50.0%, 83.9%, 38.7%, 9.7%, 48.4%, 69.4% and 79.0%, respectively; the sensitivities in the sera from 24 smear-negative TB patients were 29.2%, 79.2%, 29.2%, 12.5%, 29.2%, 54.2% and 79.2%, respectively; the specificities in the sera from 56 nonTB patients were 73.2%, 25.0%, 85.7%, 96.4%, 78.6%, 78.6% and 50.0%, respectively. Of the 2549 clinically diagnosed cases, there were 1752 pulmonary TB cases, 505 extra-pulmonary TB cases, 87 old pulmonary TB cases and 205 non-TB cases. The positive results for smear, culture, TB antibody kit B and kit H in pulmonary TB cases were 39.8%(543/1365), 48.6%(372/765), 45.8%(802/1752) and 25.2%(442/1752), respectively; the results in extra-pulmonary TB cases were 3.4%(6/178), 5.8%(4/69), 35.4%(179/505), and 11.3%(57/505), respectively; the results in old pulmonary TB cases were 0%(0/64), 0%(0/30), 32.2%(28/87), and 9.2%(8/87), respectively; and the results in non-TB cases were 0%(0/121), 0%(0/56), 21.5%(44/205), and 2.4%(5/205), respectively. Of 624 smear-positive and/or culture-positive pulmonary TB cases, the sensitivities of antibody test kits B and H were 53.0% and 36.4%, respectively. Of 901 smear-negative and/or culture-negative pulmonary TB cases, the sensitivities of antibody test kits B and H were 42.5% and 19.0%, respectively. The positive rate of antibody detection in the bacterium-positive pulmonary TB cases was significantly higher than that in the bacterium-negative pulmonary TB cases(P<0.05).Conclusion: The colloidal gold-labeled TB antibody IgG detection assay is a simple, rapid and economical method that provides a better clinical auxiliary diagnosis value on TB, especially in smear-negative pulmonary TB and extrapulmonary TB. The production, quality control, screening and evaluation of antibody detection kits are very important for its clinical application. 展开更多
关键词 TUBERCULOSIS TUBERCULOSIS ANTIBODY TEST SMEAR CULTURE
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部